Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti-PD-1 response in NSCLC.

Bullock BL, Kimball AK, Poczobutt JM, Neuwelt AJ, Li HY, Johnson AM, Kwak JW, Kleczko EK, Kaspar RE, Wagner EK, Hopp K, Schenk EL, Weiser-Evans MC, Clambey ET, Nemenoff RA.

Life Sci Alliance. 2019 May 27;2(3). pii: e201900328. doi: 10.26508/lsa.201900328. Print 2019 Jun.

2.

A study of sirolimus and an mTOR kinase inhibitor (TORKi) in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease (ADPKD).

Holditch SJ, Brown CN, Atwood DJ, Lombardi AM, Nguyen KN, Toll HW, Hopp K, Edelstein CL.

Am J Physiol Renal Physiol. 2019 May 1. doi: 10.1152/ajprenal.00051.2019. [Epub ahead of print]

PMID:
31042058
3.

Inhibition of 5-lipoxygenase decreases renal fibrosis and progression of chronic kidney disease.

Montford JR, Bauer C, Dobrinskikh E, Hopp K, Levi M, Weiser-Evans M, Nemenoff R, Furgeson SB.

Am J Physiol Renal Physiol. 2019 Apr 1;316(4):F732-F742. doi: 10.1152/ajprenal.00262.2018. Epub 2019 Jan 16.

PMID:
30649890
4.

CD8+ T cells modulate autosomal dominant polycystic kidney disease progression.

Kleczko EK, Marsh KH, Tyler LC, Furgeson SB, Bullock BL, Altmann CJ, Miyazaki M, Gitomer BY, Harris PC, Weiser-Evans MCM, Chonchol MB, Clambey ET, Nemenoff RA, Hopp K.

Kidney Int. 2018 Dec;94(6):1127-1140. doi: 10.1016/j.kint.2018.06.025. Epub 2018 Sep 21.

5.

Characterization of three ciliopathy pedigrees expands the phenotype associated with biallelic C2CD3 variants.

Boczek NJ, Hopp K, Benoit L, Kraft D, Cousin MA, Blackburn PR, Madsen CD, Oliver GR, Nair AA, Na J, Bianchi DW, Beek G, Harris PC, Pichurin P, Klee EW.

Eur J Hum Genet. 2018 Dec;26(12):1797-1809. doi: 10.1038/s41431-018-0222-3. Epub 2018 Aug 10.

PMID:
30097616
6.

Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease.

Cornec-Le Gall E, Olson RJ, Besse W, Heyer CM, Gainullin VG, Smith JM, Audrézet MP, Hopp K, Porath B, Shi B, Baheti S, Senum SR, Arroyo J, Madsen CD, Férec C, Joly D, Jouret F, Fikri-Benbrahim O, Charasse C, Coulibaly JM, Yu AS, Khalili K, Pei Y, Somlo S, Le Meur Y, Torres VE; Genkyst Study Group; HALT Progression of Polycystic Kidney Disease Group; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease, Harris PC.

Am J Hum Genet. 2018 May 3;102(5):832-844. doi: 10.1016/j.ajhg.2018.03.013. Epub 2018 Apr 26.

7.

Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease.

Porath B, Gainullin VG, Cornec-Le Gall E, Dillinger EK, Heyer CM, Hopp K, Edwards ME, Madsen CD, Mauritz SR, Banks CJ, Baheti S, Reddy B, Herrero JI, Bañales JM, Hogan MC, Tasic V, Watnick TJ, Chapman AB, Vigneau C, Lavainne F, Audrézet MP, Ferec C, Le Meur Y, Torres VE; Genkyst Study Group, HALT Progression of Polycystic Kidney Disease Group; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease, Harris PC.

Am J Hum Genet. 2016 Jun 2;98(6):1193-1207. doi: 10.1016/j.ajhg.2016.05.004.

8.

Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease.

Heyer CM, Sundsbak JL, Abebe KZ, Chapman AB, Torres VE, Grantham JJ, Bae KT, Schrier RW, Perrone RD, Braun WE, Steinman TI, Mrug M, Yu AS, Brosnahan G, Hopp K, Irazabal MV, Bennett WM, Flessner MF, Moore CG, Landsittel D, Harris PC; HALT PKD and CRISP Investigators.

J Am Soc Nephrol. 2016 Sep;27(9):2872-84. doi: 10.1681/ASN.2015050583. Epub 2016 Jan 28.

9.

Food Restriction Ameliorates the Development of Polycystic Kidney Disease.

Warner G, Hein KZ, Nin V, Edwards M, Chini CC, Hopp K, Harris PC, Torres VE, Chini EN.

J Am Soc Nephrol. 2016 May;27(5):1437-47. doi: 10.1681/ASN.2015020132. Epub 2015 Nov 4.

10.

Modulation of Polycystic Kidney Disease Severity by Phosphodiesterase 1 and 3 Subfamilies.

Ye H, Wang X, Sussman CR, Hopp K, Irazabal MV, Bakeberg JL, LaRiviere WB, Manganiello VC, Vorhees CV, Zhao H, Harris PC, van Deursen J, Ward CJ, Torres VE.

J Am Soc Nephrol. 2016 May;27(5):1312-20. doi: 10.1681/ASN.2015010057. Epub 2015 Sep 15.

11.

Utilizing magnetization transfer imaging to investigate tissue remodeling in a murine model of autosomal dominant polycystic kidney disease.

Kline TL, Irazabal MV, Ebrahimi B, Hopp K, Udoji KN, Warner JD, Korfiatis P, Mishra PK, Macura SI, Venkatesh SK, Lerman LO, Harris PC, Torres VE, King BF, Erickson BJ.

Magn Reson Med. 2016 Apr;75(4):1466-73. doi: 10.1002/mrm.25701. Epub 2015 May 13.

12.

Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria.

Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, Lieske JC, Milliner DS, Harris PC; Rare Kidney Stone Consortium.

J Am Soc Nephrol. 2015 Oct;26(10):2559-70. doi: 10.1681/ASN.2014070698. Epub 2015 Feb 2.

13.

Polycystin-1 maturation requires polycystin-2 in a dose-dependent manner.

Gainullin VG, Hopp K, Ward CJ, Hommerding CJ, Harris PC.

J Clin Invest. 2015 Feb;125(2):607-20. doi: 10.1172/JCI76972. Epub 2015 Jan 9.

14.

Effects of hydration in rats and mice with polycystic kidney disease.

Hopp K, Wang X, Ye H, Irazabal MV, Harris PC, Torres VE.

Am J Physiol Renal Physiol. 2015 Feb 1;308(3):F261-6. doi: 10.1152/ajprenal.00345.2014. Epub 2014 Dec 10.

15.
16.

Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model.

Hopp K, Hommerding CJ, Wang X, Ye H, Harris PC, Torres VE.

J Am Soc Nephrol. 2015 Jan;26(1):39-47. doi: 10.1681/ASN.2013121312. Epub 2014 Jul 3.

17.

Low-frequency human platelet antigens as triggers for neonatal alloimmune thrombocytopenia.

Peterson JA, Gitter M, Bougie DW, Pechauer S, Hopp KA, Pietz B, Szabo A, Curtis BR, McFarland J, Aster RH.

Transfusion. 2014 May;54(5):1286-93. doi: 10.1111/trf.12450. Epub 2013 Oct 16.

18.

Evidence of a third ADPKD locus is not supported by re-analysis of designated PKD3 families.

Paul BM, Consugar MB, Ryan Lee M, Sundsbak JL, Heyer CM, Rossetti S, Kubly VJ, Hopp K, Torres VE, Coto E, Clementi M, Bogdanova N, de Almeida E, Bichet DG, Harris PC.

Kidney Int. 2014 Feb;85(2):383-92. doi: 10.1038/ki.2013.227. Epub 2013 Jun 12.

19.

The mutation, a key determinant of phenotype in ADPKD.

Harris PC, Hopp K.

J Am Soc Nephrol. 2013 May;24(6):868-70. doi: 10.1681/ASN.2013040417. Epub 2013 May 16. No abstract available.

20.

A simplified method for screening siblings for HLA identity using short tandem repeat (STR) polymorphisms.

Schiller JJ, Hopp KA, Pietz BC, Bick DP, Lau EC, Ellis TM.

Hum Immunol. 2013 May;74(5):562-6. doi: 10.1016/j.humimm.2012.12.015. Epub 2013 Jan 4.

PMID:
23291277
21.

Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity.

Hopp K, Ward CJ, Hommerding CJ, Nasr SH, Tuan HF, Gainullin VG, Rossetti S, Torres VE, Harris PC.

J Clin Invest. 2012 Nov;122(11):4257-73. doi: 10.1172/JCI64313. Epub 2012 Oct 15.

22.

Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing.

Rossetti S, Hopp K, Sikkink RA, Sundsbak JL, Lee YK, Kubly V, Eckloff BW, Ward CJ, Winearls CG, Torres VE, Harris PC.

J Am Soc Nephrol. 2012 May;23(5):915-33. doi: 10.1681/ASN.2011101032. Epub 2012 Mar 1.

23.

B9D1 is revealed as a novel Meckel syndrome (MKS) gene by targeted exon-enriched next-generation sequencing and deletion analysis.

Hopp K, Heyer CM, Hommerding CJ, Henke SA, Sundsbak JL, Patel S, Patel P, Consugar MB, Czarnecki PG, Gliem TJ, Torres VE, Rossetti S, Harris PC.

Hum Mol Genet. 2011 Jul 1;20(13):2524-34. doi: 10.1093/hmg/ddr151. Epub 2011 Apr 14.

24.

Incompletely penetrant PKD1 alleles mimic the renal manifestations of ARPKD.

Vujic M, Heyer CM, Ars E, Hopp K, Markoff A, Orndal C, Rudenhed B, Nasr SH, Torres VE, Torra R, Bogdanova N, Harris PC.

J Am Soc Nephrol. 2010 Jul;21(7):1097-102. doi: 10.1681/ASN.2009101070. Epub 2010 Jun 17.

25.

Brain iron detected by SWI high pass filtered phase calibrated with synchrotron X-ray fluorescence.

Hopp K, Popescu BF, McCrea RP, Harder SL, Robinson CA, Haacke ME, Rajput AH, Rajput A, Nichol H.

J Magn Reson Imaging. 2010 Jun;31(6):1346-54. doi: 10.1002/jmri.22201.

26.

Clinical and neuroimaging findings of Cree leukodystrophy: a retrospective case series.

Harder S, Gourgaris A, Frangou E, Hopp K, Huntsman R, Lowry N, Seshia S, Lemire E, Robinson C, Tynan J.

AJNR Am J Neuroradiol. 2010 Sep;31(8):1418-23. doi: 10.3174/ajnr.A2108. Epub 2010 Apr 29.

27.

High-throughput red blood cell antigen genotyping using a nanofluidic real-time polymerase chain reaction platform.

Hopp K, Weber K, Bellissimo D, Johnson ST, Pietz B.

Transfusion. 2010 Jan;50(1):40-6. doi: 10.1111/j.1537-2995.2009.02377.x. Epub 2009 Sep 16.

PMID:
19761548
28.

Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease.

Rossetti S, Kubly VJ, Consugar MB, Hopp K, Roy S, Horsley SW, Chauveau D, Rees L, Barratt TM, van't Hoff WG, Niaudet P, Torres VE, Harris PC.

Kidney Int. 2009 Apr;75(8):848-55. doi: 10.1038/ki.2008.686. Epub 2009 Jan 21. Erratum in: Kidney Int. 2010 Feb;77(4):368. Niaudet, W Patrick [corrected to Niaudet, Patrick]. Kidney Int. 2009 Jun;75(12):1359. Kidney Int. 2009 Jun 2;75(12):1359.

29.

Mineralization of the deep gray matter with age: a retrospective review with susceptibility-weighted MR imaging.

Harder SL, Hopp KM, Ward H, Neglio H, Gitlin J, Kido D.

AJNR Am J Neuroradiol. 2008 Jan;29(1):176-83. Epub 2007 Nov 7.

30.

Genetic variability at the human FMO1 locus: significance of a basal promoter yin yang 1 element polymorphism (FMO1*6).

Hines RN, Luo Z, Hopp KA, Cabacungan ET, Koukouritaki SB, McCarver DG.

J Pharmacol Exp Ther. 2003 Sep;306(3):1210-8. Epub 2003 Jun 26.

PMID:
12829732
31.

Alternative processing of the human FMO6 gene renders transcripts incapable of encoding a functional flavin-containing monooxygenase.

Hines RN, Hopp KA, Franco J, Saeian K, Begun FP.

Mol Pharmacol. 2002 Aug;62(2):320-5.

PMID:
12130684
32.

Heme oxygenase-1 induction attenuates inducible nitric oxide synthase expression and proteinuria in glomerulonephritis.

Datta PK, Koukouritaki SB, Hopp KA, Lianos EA.

J Am Soc Nephrol. 1999 Dec;10(12):2540-50.

33.

Effects of intrarenal infusion of 17-octadecynoic acid on renal antihypertensive mechanisms in anesthetized rabbits.

Evans RG, Day KH, Roman RJ, Hopp KH, Anderson WP.

Am J Hypertens. 1998 Jul;11(7):803-12.

PMID:
9683041
34.

Localization of cytochrome P-450 4A isoforms along the rat nephron.

Ito O, Alonso-Galicia M, Hopp KA, Roman RJ.

Am J Physiol. 1998 Feb;274(2):F395-404. doi: 10.1152/ajprenal.1998.274.2.F395.

PMID:
9486235
35.
37.

Expression of mRNA for vasoactive intestinal peptide in rat small intestine.

Stadelmann AM, Telford GL, Appel DA, Walgenbach-Telford S, Hopp K, Meier DA, Koch TR.

Mol Cell Endocrinol. 1996 Jan 15;116(1):31-7.

PMID:
8822262
38.

Regional concentration of basic fibroblast growth factor in normal and benign hyperplastic human prostates.

Begun FP, Story MT, Hopp KA, Shapiro E, Lawson RK.

J Urol. 1995 Mar;153(3 Pt 1):839-43.

PMID:
7532239
39.

Expression of mRNA for vasoactive intestinal peptide in normal human colon and during inflammation.

Schulte-Bockholt A, Fink JG, Meier DA, Otterson MF, Telford GL, Hopp K, Koch TR.

Mol Cell Biochem. 1995 Jan 12;142(1):1-7.

PMID:
7753037
40.
41.

Gene expression and transcript size of the prepro-peptide VIP/PHM-27 in normal human tissue.

Schulte-Bockholt A, Meier DA, Hopp K, Stadelmann A, Otterson MF, Telford GL, Koch TR.

Neurosci Lett. 1993 Dec 24;164(1-2):101-4.

PMID:
8152582
43.

In vitro antitrypanosomal activity of certain alkaloids against Trypanosoma lewisi.

Hopp KH, Cunningham LV, Bromel MC, Schermeister LJ, Khalil SK.

Lloydia. 1976 Sep-Oct;39(5):375-7. No abstract available.

PMID:
798093
44.

[Comparison of blood pressure reactions under stress in normotonic patients with and without an anamnesis of hypertension].

Hopp K, Hausdörfer A, Höller E, Noffke U, Piekarski K, Schulte W.

Verh Dtsch Ges Inn Med. 1976;82 Pt 2:1282-4. German. No abstract available.

PMID:
1029980
45.

[Influences of the investigator and the blind technique during a pharmacological experiment of short duration in man].

von Eiff AW, Frotscher U, Hopp K.

Klin Wochenschr. 1971 Oct 15;49(20):1133-8. German. No abstract available.

PMID:
5122435
46.

[Use of fluorescent spectrography in detection of carcinogenic hydrocarbons].

HOPP K, NOVOTNA M, SULA J.

Cas Lek Cesk. 1955 Sep 23;94(39):1041-4. Czech. No abstract available.

PMID:
13261138
47.

[Examination of smoked food products for 3,4-benzopyrene].

DOBES M, HOPP K, SULA J.

Cesk Onkol. 1954;1(3-4):254-66. Czech. No abstract available.

PMID:
14390632
48.

[Effects of adrenal cortex hormones; observations in pulmonary tuberculosis].

HOPP K, SERKE U.

Munch Med Wochenschr. 1953 Apr 17;95(16):489-91. Undetermined Language. No abstract available.

PMID:
13072417

Supplemental Content

Support Center